• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(-)-11-羟基-δ8-四氢大麻酚-二甲基庚基对大鼠的心血管影响。

Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats.

作者信息

Vidrio H, Sánchez-Salvatori M A, Medina M

机构信息

Department of Pharmacology, School of Medicine, National University of Mexico, D.F., Mexico.

出版信息

J Cardiovasc Pharmacol. 1996 Aug;28(2):332-6. doi: 10.1097/00005344-199608000-00022.

DOI:10.1097/00005344-199608000-00022
PMID:8856492
Abstract

The effects of the stereochemically pure psychoactive cannabinoid (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl (HU-210) on blood pressure (BP) and heart rate (HR) were determined in rats. In pentobarbital-anesthetized animals, the compound produced dose-related, long-lasting hypotension and bradycardia at doses between 10 and 1,000 micrograms/kg. BP began to decrease immediately after drug administration, and in no case was an initial pressor response observed. Previous vagotomy (VX) or pretreatment with 6-hydroxydopamine (6-OHDA) did not affect hypotension. Bradycardia was inhibited by VX, but only 60 min after administration of HU-210; it was enhanced by 6-OHDA. The cannabinoid blocked reflex bradycardia induced by phenylephrine (PE). HU-210 also decreased BP and HR in conscious rats. Hypotension lasted 2 h, whereas bradycardia was still present 8 h after drug administration. HU-210 thus shares with delta 9-tetrahydrocannabinol (THC) the ability to decrease BP and HR, but is 5-10 times more potent than the natural compound. Its lack of an initial pressor effect, such as that described for THC, could be related to its specificity for the type-1 cannabinoid (CB1) receptor. Hypotension and bradycardia after HU-210 administration are not due to sympathetic withdrawal. Enhanced parasympathetic tone is involved in bradycardia only at a late stage of the response.

摘要

研究了立体化学纯的精神活性大麻素(-)-11-羟基-δ8-四氢大麻酚-二甲基庚基(HU-210)对大鼠血压(BP)和心率(HR)的影响。在戊巴比妥麻醉的动物中,该化合物在10至1000微克/千克的剂量下产生剂量相关的、持久的低血压和心动过缓。给药后血压立即开始下降,且未观察到初始升压反应。先前的迷走神经切断术(VX)或用6-羟基多巴胺(6-OHDA)预处理均不影响低血压。VX可抑制心动过缓,但仅在给予HU-210后60分钟出现;6-OHDA可增强心动过缓。该大麻素可阻断去氧肾上腺素(PE)诱导的反射性心动过缓。HU-210也可降低清醒大鼠的血压和心率。低血压持续2小时,而给药后8小时仍存在心动过缓。因此,HU-210与δ9-四氢大麻酚(THC)一样具有降低血压和心率的能力,但效力比天然化合物强5至10倍。其缺乏如THC所描述的初始升压作用可能与其对1型大麻素(CB1)受体的特异性有关。给予HU-210后的低血压和心动过缓并非由于交感神经抑制。增强的副交感神经张力仅在反应的后期参与心动过缓。

相似文献

1
Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats.(-)-11-羟基-δ8-四氢大麻酚-二甲基庚基对大鼠的心血管影响。
J Cardiovasc Pharmacol. 1996 Aug;28(2):332-6. doi: 10.1097/00005344-199608000-00022.
2
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.大麻素在大鼠中通过类CB1大麻素受体介导引起低血压和心动过缓。
J Pharmacol Exp Ther. 1997 Jun;281(3):1030-7.
3
Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.大麻素的血流动力学效应:由大麻素CB(1)受体介导的冠状动脉和脑血管舒张。
Eur J Pharmacol. 2001 Jul 6;423(2-3):203-10. doi: 10.1016/s0014-2999(01)01112-8.
4
Cardiovascular effects of delta 9- and delta 9(11)-tetrahydrocannabinol and their interaction with epinephrine.
Life Sci. 1987 Jul 6;41(1):79-87. doi: 10.1016/0024-3205(87)90559-5.
5
Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.9-四氢大麻酚通过大麻素CB1受体抑制大鼠的胃动力。
Eur J Pharmacol. 1999 Apr 29;371(2-3):187-96. doi: 10.1016/s0014-2999(99)00165-x.
6
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats.花生四烯乙醇胺对麻醉和清醒的正常血压及高血压大鼠的心血管作用。
Hypertension. 1997 May;29(5):1204-10. doi: 10.1161/01.hyp.29.5.1204.
7
Effects of delta-9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in rats.
Jpn J Pharmacol. 1980 Aug;30(4):493-502. doi: 10.1254/jjp.30.493.
8
Antinociception and cardiovascular responses produced by intravenous morphine: the role of vagal afferents.静脉注射吗啡产生的抗伤害感受和心血管反应:迷走神经传入纤维的作用
Brain Res. 1991 Mar 15;543(2):256-70. doi: 10.1016/0006-8993(91)90036-u.
9
[Paticipation of cannabinoid receptors in the regulation of cardiac rhythm and cardiac contractility].
Ross Fiziol Zh Im I M Sechenova. 2006 Apr;92(4):429-39.
10
Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats.
Eur J Pharmacol. 1998 Feb 26;344(1):77-86. doi: 10.1016/s0014-2999(97)01560-4.

引用本文的文献

1
Acute and subacute cardiovascular effects of synthetic cannabinoid JWH-018 in rat.合成大麻素JWH-018对大鼠的急性和亚急性心血管影响。
Forensic Toxicol. 2025 Apr 16. doi: 10.1007/s11419-025-00720-9.
2
The Old and the New: Cardiovascular and Respiratory Alterations Induced by Acute JWH-018 Administration Compared to Δ-THC-A Preclinical Study in Mice.新旧对比:急性 JWH-018 给药引起的心血管和呼吸系统改变与小鼠体内 Δ-THC-A 的临床前研究对比。
Int J Mol Sci. 2023 Jan 13;24(2):1631. doi: 10.3390/ijms24021631.
3
Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.
大麻素受体 1 抑制在慢性肾脏病中的应用:一个新的治疗工具箱。
Front Endocrinol (Lausanne). 2021 Jul 7;12:720734. doi: 10.3389/fendo.2021.720734. eCollection 2021.
4
Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (∆-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation.在原肠胚形成阶段,斑马鱼的运动神经元发育会因短暂(5 小时)暴露于 THC(四氢大麻酚)或 CBD(大麻二酚)而改变。
Sci Rep. 2018 Jul 12;8(1):10518. doi: 10.1038/s41598-018-28689-z.
5
The endocannabinoid system in cardiovascular function: novel insights and clinical implications.内源性大麻素系统在心血管功能中的作用:新的见解和临床意义。
Clin Auton Res. 2018 Feb;28(1):35-52. doi: 10.1007/s10286-017-0488-5. Epub 2017 Dec 8.
6
Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?大麻素引起的三相血压反应:我们是否了解其机制?
Br J Pharmacol. 2012 Apr;165(7):2073-88. doi: 10.1111/j.1476-5381.2011.01747.x.
7
Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.心血管疾病中的内源性大麻素系统——新的药物治疗机遇
J Pharm Bioallied Sci. 2011 Jul;3(3):350-60. doi: 10.4103/0975-7406.84435.
8
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.大麻素作为心血管疾病的治疗药物:一个充满激情与幻想的故事。
Br J Pharmacol. 2007 Jun;151(4):427-40. doi: 10.1038/sj.bjp.0707261. Epub 2007 Apr 23.
9
The endocannabinoid system as an emerging target of pharmacotherapy.内源性大麻素系统作为药物治疗的一个新兴靶点。
Pharmacol Rev. 2006 Sep;58(3):389-462. doi: 10.1124/pr.58.3.2.
10
Cardiovascular pharmacology of cannabinoids.大麻素的心血管药理学
Handb Exp Pharmacol. 2005(168):599-625. doi: 10.1007/3-540-26573-2_20.